Pediatric HIV represents one of the greatest success stories in modern medicine. From a uniformly fatal diagnosis in the 1980s, we now have the tools to prevent mother-to-child transmission and enable children with HIV to live long, healthy lives. However, this requires early diagnosis, prompt treatment, and lifelong management. Understanding pediatric HIV is essential for every healthcare provider working with children.
🔄 How Children Get HIV: Routes of Transmission
Understanding transmission routes is key to prevention and early intervention.
Vertical Transmission (Mother-to-Child)
Most common route: 90% of pediatric HIV cases
Timing of transmission:
- During pregnancy: 15-30%
- During delivery: 50-70%
- During breastfeeding: 5-20%
Horizontal Transmission
Less common in children but important:
- Blood transfusions (screened in most countries since 1985)
- Contaminated needles or medical equipment
- Sexual abuse or assault
- Adolescent sexual activity
Risk Factors for Vertical Transmission
- High maternal viral load (>100,000 copies/mL)
- Low maternal CD4 count
- Rupture of membranes >4 hours
- Chorioamnionitis
- Breastfeeding (especially mixed feeding)
- Vaginal delivery (vs. C-section when viral load high)
🔍 Clinical Presentation: How HIV Looks Different in Children
Children with HIV present differently than adults. Their immature immune systems and rapid growth create unique challenges.
Rapid Progressors
20-25% of infected infants
Symptoms develop within first few months of life:
- Failure to thrive (poor weight gain)
- Persistent oral thrush
- Hepatosplenomegaly
- Lymphadenopathy
- Recurrent bacterial infections
- Developmental delay
Slow Progressors
75-80% of infected infants
Symptoms develop more gradually, often after 1-2 years:
- Recurrent respiratory infections
- Chronic diarrhea
- Generalized lymphadenopathy
- Parotid gland enlargement
- Skin conditions (eczema, molluscum)
- Mild developmental delay
WHO Clinical Staging for Pediatric HIV
Stage 1: Asymptomatic
Stage 2: Mild symptoms (oral thrush, persistent lymphadenopathy)
Stage 3: Moderate symptoms (unexplained chronic diarrhea, severe bacterial infections)
Stage 4: AIDS-defining conditions (PCP, CMV, wasting syndrome)
🧪 Diagnosis: The Challenge of Maternal Antibodies
The Problem with Standard Testing
Maternal HIV antibodies cross the placenta and persist in the infant for up to 18 months. This means standard antibody tests (ELISA, rapid tests) cannot distinguish between:
- Antibodies from the mother (infant not infected)
- Antibodies produced by the infant (infant infected)
Virological Testing (Gold Standard)
HIV DNA PCR or HIV RNA PCR
Detects the virus directly, not antibodies.
Testing Schedule:
- First test: 2-4 weeks of age
- Second test: 4-8 weeks of age
- Third test: 4-6 months of age
- Antibody test: ≥18 months to confirm
Diagnostic Algorithm
For infants born to HIV+ mothers:
- Start ART immediately after birth (do not wait for test results)
- Test with PCR at 2-4 weeks
- If positive: confirm with second PCR, continue ART
- If negative: continue ART through breastfeeding period
- Final antibody test at ≥18 months
💊 Treatment: Pediatric Antiretroviral Therapy (ART)
Treatment principles differ significantly between children and adults due to growth, development, and pharmacokinetics.
When to Start ART
For ALL children with HIV, regardless of CD4 or clinical stage!
This represents a major shift from previous "wait and watch" approaches.
Rationale: Early treatment preserves immune function, reduces viral reservoirs, and improves neurodevelopment.
First-Line Regimens (WHO)
Preferred for children <3 years or <10 kg:
- ABC + 3TC + LPV/r (liquid formulations)
Preferred for children ≥3 years or ≥10 kg:
- TDF/AZT + 3TC/FTC + EFV
- Or: ABC + 3TC + DTG (increasingly preferred)
| Drug Class | Pediatric Options | Key Considerations | Common Side Effects |
|---|---|---|---|
| NRTIs | AZT, 3TC, ABC, TDF, FTC | AZT: Bone marrow suppression ABC: Hypersensitivity TDF: Renal/bone toxicity |
Anemia, nausea, lipodystrophy |
| NNRTIs | EFV, NVP | EFV: Neuropsychiatric effects NVP: Rash, hepatotoxicity |
Rash, liver enzyme elevation |
| PIs | LPV/r, ATV/r | Require refrigeration High pill burden |
Diarrhea, lipid abnormalities |
| INSTIs | DTG, RAL | DTG: Preferred for ≥30 kg RAL: Twice daily dosing |
Insomnia, headache, weight gain |
Special Pediatric Challenges
- Dosing by weight: Must recalculate with every clinic visit as child grows
- Formulations: Need child-friendly formulations (syrups, dispersible tablets)
- Palatability: Bad taste leads to adherence problems
- Disclosure: Age-appropriate disclosure process starting around age 6-8
- Transition to adult care: Planned transition starting in early adolescence
🛡️ Prevention of Mother-to-Child Transmission (PMTCT)
The Four-Pronged Approach (WHO)
Prong 1: Prevent HIV in Women
Primary prevention in women of childbearing age
Prong 3: Prevent Transmission
ART during pregnancy, delivery, breastfeeding
Prong 4: Provide Care
Treatment, care, support for mother and child
PMTCT Interventions That Work
During pregnancy: Maternal ART to achieve undetectable viral load
During delivery: IV AZT if viral load >1000 copies/mL; consider C-section if viral load high
Infant prophylaxis: All HIV-exposed infants receive ART prophylaxis for 4-12 weeks
Feeding: Exclusive breastfeeding with maternal ART OR exclusive formula feeding
⚠️ Common Complications in Pediatric HIV
Infectious Complications
Pneumocystis jirovecii Pneumonia (PCP):
- Most common AIDS-defining illness in children
- Peak incidence: 3-6 months
- Prophylaxis: Cotrimoxazole from 4-6 weeks until confirmed HIV-negative or immune reconstitution
Tuberculosis: 20x higher risk than HIV-negative children
Growth & Development
- HIV wasting syndrome: Weight loss >10%, chronic diarrhea, weakness
- Growth failure: Height and weight <3rd percentile
- HIV encephalopathy: Developmental delay, microcephaly, spasticity
- Neurocognitive impairment: Learning difficulties, behavioral problems
Other Complications
- Lymphoid interstitial pneumonitis (LIP): Chronic lung disease with clubbing
- Cardiomyopathy: HIV-related or ART-related
- Renal disease: HIV-associated nephropathy
- Malignancies: Lymphomas (especially Burkitt's), Kaposi sarcoma
📊 Monitoring Pediatric HIV Patients
| Parameter | Frequency | Target/Goal | Clinical Significance |
|---|---|---|---|
| Viral Load | Baseline, then every 3-6 months | Undetectable (<50 copies/mL) | Primary measure of treatment success |
| CD4 Count/% | Every 3-6 months | CD4% >25% (age <5) CD4 count >500 (age ≥5) |
Immune reconstitution |
| Growth Parameters | Every visit | Following growth curve | Early sign of treatment failure or complications |
| Developmental Assessment | Every 6-12 months | Age-appropriate milestones | Detect HIV encephalopathy early |
| Drug Toxicity Monitoring | As per drug regimen | Normal labs | Prevent ART complications |
| Adherence Assessment | Every visit | >95% adherence | Critical for treatment success |
📝 Medical Abbreviations Explained
Medical literature uses many abbreviations. Here's a quick reference for the terms used in this article:
HIV/AIDS Terms
- HIV: Human Immunodeficiency Virus
- AIDS: Acquired Immunodeficiency Syndrome
- ART: Antiretroviral Therapy
- PMTCT: Prevention of Mother-to-Child Transmission
- PCP: Pneumocystis jirovecii Pneumonia
- PCR: Polymerase Chain Reaction
- DNA/RNA: Deoxyribonucleic Acid / Ribonucleic Acid
Antiretroviral Drug Classes
- NRTI: Nucleoside Reverse Transcriptase Inhibitor
- NNRTI: Non-Nucleoside Reverse Transcriptase Inhibitor
- PI: Protease Inhibitor
- INSTI: Integrase Strand Transfer Inhibitor
- /r: boosted with Ritonavir (e.g., LPV/r)
Common ARV Drugs
- AZT: Zidovudine (Zidolam)
- 3TC: Lamivudine
- ABC: Abacavir
- TDF: Tenofovir Disoproxil Fumarate
- FTC: Emtricitabine
- EFV: Efavirenz
- NVP: Nevirapine
- LPV/r: Lopinavir/Ritonavir
- DTG: Dolutegravir
- RAL: Raltegravir
Medical & Laboratory Terms
- CD4: Cluster of Differentiation 4 (immune cells)
- WHO: World Health Organization
- ELISA: Enzyme-Linked Immunosorbent Assay
- TB: Tuberculosis
- CMV: Cytomegalovirus
- LIP: Lymphoid Interstitial Pneumonitis
- IV: Intravenous
- PO: Per Os (by mouth)
- IM: Intramuscular
- Always confirm drug names and doses – some abbreviations can be confused (e.g., AZT vs AZA)
- In clinical practice, write out drug names fully on prescriptions to avoid errors
- Local guidelines may use different abbreviations – check your institution's standards
| Abbreviation | Meaning | Example |
|---|---|---|
| OD | Once daily | Take 1 tablet OD |
| BD/BID | Twice daily | Take 1 teaspoon BD |
| TDS/TID | Three times daily | Take 1 capsule TDS |
| QID | Four times daily | Take 2 tablets QID |
| PRN | As needed | Take for pain PRN |
| AC | Before meals | Take 30 minutes AC |
| PC | After meals | Take with food PC |
💎 Clinical Pearls and High-Yield Points
Essential Pearls for Clinical Practice
1. Universal "Test and Treat": All children with HIV should start ART immediately upon diagnosis, regardless of CD4 or clinical stage.
2. PCR for Diagnosis: Never use antibody tests for children <18 months. Use HIV DNA/RNA PCR.
3. PMTCT Works: With full interventions, mother-to-child transmission is <1%.
4. PCP Prophylaxis: All HIV-exposed infants need cotrimoxazole from 4-6 weeks until HIV status is confirmed negative.
5. Growth = Vital Sign: Falling off growth curve may be the first sign of treatment failure.
6. Disclosure is a Process: Start age-appropriate disclosure around age 6-8, complete by adolescence.
7. Plan Transitions: Begin transition to adult care in early adolescence, complete by age 24.
Success Story: The "Mississippi Baby" and Beyond
In 2013, a child born with HIV in Mississippi received ART within 30 hours of birth and remained off treatment with undetectable virus for 27 months before viral rebound. While not a cure, this case demonstrated that very early ART might prevent establishment of viral reservoirs. This finding reinforced the "Treat All" approach and the importance of testing and treating infants immediately after birth.
🌟 The Future: Ending Pediatric HIV
We now have all the tools needed to virtually eliminate new pediatric HIV infections:
- Effective PMTCT programs can reduce transmission to <1%
- Early diagnosis through PCR testing
- Effective, well-tolerated ART regimens
- Support for adherence and retention in care
- Integrated family-centered care
The Challenge: Not scientific, but implementation. Reaching all pregnant women with testing, ensuring all HIV+ pregnant women receive ART, testing all exposed infants, and linking all infected children to care.
As healthcare providers, our role extends beyond clinical care to advocacy, education, and system strengthening to ensure no child is born with HIV when we have the means to prevent it.